protocolSection identificationModule nctId: NCT06340906, orgStudyIdInfo id: 4573, secondaryIdInfos id: UCI 23-29, type: OTHER, domain: CFCCC, briefTitle: Electroacupuncture in Symptom Management After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-15, primaryCompletionDateStruct date: 2025-11-15, completionDateStruct date: 2026-01-30, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: University of California, Irvine, class: OTHER, descriptionModule briefSummary: The investigators are conducting this research study is to evaluate the feasibility (recruitment, compliance, safety, and acceptance) of using electroacupuncture (EA) to manage complex symptoms such as pain, nausea/vomiting, diarrhea, and insomnia in patients who have undergone Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Additionally, the investigators are aiming to determine the effectiveness of EA in reducing these symptoms, and to examine how EA impacts important biomarkers, or proteins in the blood, that can be used as indicators or signs of these symptoms., conditionsModule conditions: Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: This is a single-arm, prospective pilot/feasibility study., primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Electroacupuncture, outcomesModule primaryOutcomes measure: Feasibility in utilizing an EA for patients who have undergone Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy - Number of Patients Recruited, primaryOutcomes measure: Feasibility in utilizing an EA for patients who have undergone Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy - Patient Recruitment Rate, primaryOutcomes measure: Feasibility in utilizing an EA for patients who have undergone Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy - Reasons for Abstaining from Participation, primaryOutcomes measure: Feasibility in utilizing an EA for patients who have undergone Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy - Recruitment Duration, primaryOutcomes measure: Feasibility in utilizing an EA for patients who have undergone Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy - Number of Completed Electroacupuncture Sessions, primaryOutcomes measure: Feasibility in utilizing an EA for patients who have undergone Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy - Proportion of Completed Electroacupuncture Sessions, secondaryOutcomes measure: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Symptoms - EORTC QLQ-C30, secondaryOutcomes measure: Efficacy of EA in managing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Symptoms - EORTC QLQ-C30, secondaryOutcomes measure: Efficacy of EA in managing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Symptoms - FACT-Cog version 3, secondaryOutcomes measure: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Symptoms - FACT-Cog version 3, otherOutcomes measure: Biomarkers - Plasma (pg/mL), otherOutcomes measure: Vital Signs - Blood Pressure (mmHg), otherOutcomes measure: Vital Signs - Heart Rate (bpm), otherOutcomes measure: Vital Signs - Body Temperature (C), otherOutcomes measure: Vital Signs - Respiration Rate (breaths/minute), otherOutcomes measure: Vital Signs - Oxygen Saturation Rate (%), otherOutcomes measure: Height (feet and inches), otherOutcomes measure: Weight (kg), otherOutcomes measure: Incidence of Treatment-Emergent Adverse Events - Safety Monitoring, otherOutcomes measure: Biomarkers - Plasma BDNF (pg/ml), otherOutcomes measure: Biomarkers - Plasma cytokines (IL-1β, IL-4, IL-6, IL-8, IL-10, TNF-alpha, pg/mL), otherOutcomes measure: Mitochondrial DNA content, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: UCI Health Susan Samueli Integrative Health Institute, city: Irvine, state: California, zip: 92697, country: United States, contacts name: Matthew Heshmatipour, BSc, role: CONTACT, email: mheshmat@hs.uci.edu, geoPoint lat: 33.66946, lon: -117.82311, hasResults: False